NCCN presented new NCCN Clinical Practice Guidelines in Oncology(TM) for Primary Cutaneous B-Cell Lymphoma as well as important updates to the NCCN Guidelines for Non-Hodgkin's Lymphomas at the NCCN 14th Annual Conference. The new NCCN Guidelines were written to distinguish Primary B-Cell Lymphomas from their nodal counterparts and provide clinicians with treatment recommendations. Andrew D. Zelenetz, MD, PhD, and Steven M. Horowitz, MD, both of Memorial Sloan-Kettering Cancer Center, presented the updates to the NCCN Guidelines.
HOLLYWOOD, Fla., March 13 /PRNewswire-USNewswire/ -- The addition of new NCCN Clinical Practice Guidelines in Oncology(TM) for Primary Cutaneous B-Cell Lymphoma was a highlight at the NCCN 14th Annual Conference on Friday, March 13. The new NCCN Guidelines are encompassed within the NCCN Guidelines for Non-Hodgkin's Lymphomas (NHL), which also had several notable updates presented by the chair of the NCCN Guidelines Panel for NHL, Andrew D. Zelenetz, MD, PhD, of Memorial Sloan-Kettering Cancer Center.
Steven M. Horwitz, MD, of Memorial Sloan-Kettering Cancer Center, presented the new NCCN Guidelines for Cutaneous B-Cell Lymphoma pointing out the unique clinical features that distinguish Primary Cutaneous B-Cell Lymphomas from their nodal counterparts and the need for clinical practice guidelines given the commonality of B-Cell Lymphomas.
Dr. Horowitz explained that Primary Cutaneous B-Cell Lymphoma is a B-Cell Lymphoma presenting in the skin where there is no evidence of extracutaneous disease on a complete staging work-up. They may appear on the skin as a reddish rash, lump or nodule and, because they tend to develop in the dermis, or second layer of the skin, may have a slightly raised and smooth appearance.
The new NCCN Guidelines for Cutaneous B-Cell Lymphoma stress consulting a pathologist familiar with diagnosing Primary Cutaneous B-Cell Lymphoma and r
'/>"/>
| SOURCE National Comprehensive Cancer Network Copyright©2009 PR Newswire. All rights reserved |